Pyxis Oncology has announced positive preliminary data from its ongoing Phase I clinical studies evaluating micvotabart pelidotin (MICVO) in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). MICVO is an antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the… Read More
Avacta Therapeutics has announced new data in patients with salivary gland cancer (SGC) enrolled in the ongoing Phase Ib trial of faridoxorubicin (AVA6000). The data show confirmed partial and minor responses, consistent with data previously reported from the Phase Ia part of the study. … Read More
A study into treatments for chronic lymphocytic leukaemia and small lymphocytic leukaemia (CLL/SLL) has found that Jaypirca (pirtobrutinib) is more effective than Imbruvica (ibrutinib). The Phase III, first-of-its-kind BRUIN CLL-314 trial found that pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib. Pirtobrutinib, developed by Eli… Read More
Oncology company Terns Pharmaceuticals has announced encouraging results showing its candidate could be a best-in-class treatment for relapsed and refractory chronic myeloid leukaemia (CML). The Phase I trial of TERN-701 showed a 64% major molecular response (MMR) achievement rate across all efficacy evaluable patients, also proving its safe and… Read More
Biotechnology company Arcellx has announced positive data from the Phase II study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM). Results from the iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a fourth-line or higher (4L+) RRMM population,… Read More
Biotechnology company Miltenyi Biotec has announced encouraging results from its CAR-T therapy for patients with second-line, relapsed or refractory large B-cell lymphoma. Primary analysis of candidate zamtocabtagene autoleucel (zamto-cel) showed the therapy demonstrated significant and clinically meaningful superiority over chemoimmunotherapy. The candidate was evaluated in the DALY 2-EU trial, conducted… Read More
The first patient has been dosed in the Phase I clinical trial of ART-101 in men with metastatic castration-resistant prostate cancer (mCRPC). ART-101 is a novel receptor-based targeting small molecule developed for the imaging and treatment of prostate cancer. The therapy targets prostate-specific membrane antigen (PSMA) and,… Read More
Drug discovery company Lunai Bioworks has secured its first Letter of Intent (LOI) to license its next-generation immune cell therapy, advancing the treatment to clinic. Lunai’s Dendritic Cell Combination Therapy (DCCT) achieved complete regression of both primary and metastatic pancreatic tumours with no recurrence in humanised pre-clinical models. Read More
Researchers have found that that FOLFIRINOX, a chemotherapy used for pancreatic cancer, may improve survival in advanced biliary tract cancer (BTC) patients. A new collaborative study from Pusan National University and Yonsei University suggests that the FOLFIRINOX regimen showed numerically improved survival outcomes compared to current standards… Read More
Biotechnology company Imviva Biotech is set to present data on its CAR-T pipeline at the American Society of Haematology (ASH) Annual Meeting. Imviva will reveal progress in allogeneic cell therapy candidates being developed for multiple haematological conditions, including T-cell acute lymphoblastic leukaemia, lymphoblastic lymphoma, acute myeloid leukaemia, B-cell… Read More
New research has identified a precision therapy which could stop breast cancer at the source. Researchers at the University of California San Diego School of Medicine used an antibody-drug conjugate (ADC) to target a cell-surface protein known as FZD7. FZD7 is present on cells with high tumour-initiating potential in… Read More
Life sciences company 10x Genomics has launched an initiative to create a pan-cancer spatial atlas driven by spatial research in the Asia-Pacific region. As part of the initiative, 10x Genomics has partnered with the Garvan Institute of Medical Research in Australia and the University of Tokyo in… Read More
Researchers have demonstrated how computational simulations can unravel the complex role of water molecules in drug binding. The study focused on B-cell lymphoma 6 (BCL6), a protein implicated in several cancers. Using advanced computational techniques, the team showed how subtle changes in drug molecules can disrupt or… Read More
Nuclear materials recycled in the UK are set to be used to develop cutting-edge cancer treatments. A new government-backed project, led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), will use a radionuclide called lead-212 to create treatments known as Targeted Alpha Therapies. The project has… Read More
A world-first clinical trial is launching to test an experimental vaccine designed to prevent lung cancer in people at high risk of the disease. Lung cancer remains the leading cause of cancer death in the UK, accounting for 20% of cancer deaths each year. Researchers… Read More
Researchers at Chiba University in Japan have developed a new nasal therapeutic vaccine as a non-invasive treatment option for cervical cancer. Cervical cancer is primarily caused by the human papillomavirus (HPV), but there are no approved therapeutic medicines to treat existing infections or HPV-associated cancers. … Read More
